Advances in Treatment of Acute Myeloid Leukemia

Sameh Abdelmoneem Mohammed Ali

Department of Micro-Nano Mechanical Science and Engineering, Nagoya University, Japan
Department of Pharmacology & Toxicology, Faculty of Pharmacy, Beni-Suef University, Egypt

Dr. Sameh Abdelmoneem Mohammed Ali, Department of Micro-Nano Mechanical Science and Engineering, Nagoya University, Japan.

Keywords: Acute Myeloid Leukemia; Genetic Mutations; Nanofabrications

Abstract

Minderman et al, in a published article, demonstrate that multidrug resistance and genetic mutations of acute myeloid leukemia as well as patient relapse may constitute the main leading causes for the creation of innovative perspectives and the development of more specific medications for targeted genes [1]. Consequently, this serious disease becomes one of current emerging issues all over the world. Although cytarabine and anthracycline combination is still considered as a standard cure, clinical treatment outcomes of this conventional combination is poor and resulting in death of millions of patients annually [2].

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).